- Home
- HBNC vs OLMA Comparison
HBNC vs OLMA Comparison
Compare HBNC & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HBNC | OLMA |
|---|---|---|
| Founded | 1873 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 962.4M | 863.0M |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | HBNC | OLMA |
|---|---|---|
| Price | $19.41 | $10.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $21.00 | ★ $44.89 |
| AVG Volume (30 Days) | 432.2K | ★ 1.5M |
| Earning Date | 04-22-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.57% | N/A |
| EPS Growth | N/A | ★ 15.00 |
| EPS | ★ 0.51 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.52 | N/A |
| P/E Ratio | $37.92 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.84 | $4.12 |
| 52 Week High | $19.93 | $36.26 |
Technical Indicators
Market Signals| Indicator | HBNC | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 59.72 | 30.99 |
| Support Level | $17.18 | $7.79 |
| Resistance Level | N/A | $11.54 |
| Average True Range (ATR) | 0.44 | 0.73 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 67.03 | 17.18 |
Price Performance
Historical ComparisonAbout HBNC Horizon Bancorp Inc.
Horizon Bancorp (IN) is a United States-based holding company providing banking services. It is engaged in providing commercial and retail banking services, corporate and individual trust and agency services, and other services incident to banking. The company also provides commercial loans, real estate loans, mortgage warehouse loans, consumer loans, and other credit facilities. The company has one principal business segment, commercial banking.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.